Acute myeloid leukemia therapy elicits durable complete response in chemoradio-resistant metastatic paraganglioma. uri icon

Overview

abstract

  • Few effective therapeutic options exist for patients with metastatic paraganglioma (PGL). We report the case of a 16-year-old male who developed acute myeloid leukemia (AML) 30 months following the treatment for metastatic PGL. PGL had been refractory to 131 I-meta-iodobenzylguanidine and temozolomide therapy. However, there was a major reduction in primary tumor allowing its gross total resection, and complete resolution of metastatic disease following AML-directed therapy that included daunorubicin, cytarabine, and etoposide. He remains in remission for both AML and PGL, 48 months post AML chemotherapy. Alternative chemotherapeutic agents should be considered for metastatic PGL resistant to conventional therapy.

publication date

  • November 2, 2016

Research

keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • Cytarabine
  • Daunorubicin
  • Etoposide
  • Leukemia, Myeloid, Acute
  • Paraganglioma

Identity

PubMed Central ID

  • PMC5535780

Scopus Document Identifier

  • 84996644259

Digital Object Identifier (DOI)

  • 10.1002/pbc.26314

PubMed ID

  • 27804217

Additional Document Info

volume

  • 64

issue

  • 5